The Associations Between Dietary Choline, Genetics and Anxiety/Depression

The Association Between Dietary Choline, Genetics and Anxiety/Depression

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04036552

Enrollment

Registered

2019-07-29

Start date

2019-08-01

Completion date

2019-10-03

Last updated

2019-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety, Choline Deficiency, Depression

Brief summary

The associations between dietary choline, genetics and anxiety/depression

Detailed description

Choline, previously considered to be a vitamin, is an essential nutrient involved in a plethora of biological pathways. Choline status is thought to be associated with depression and anxiety, however, the lack of evidence regarding the exact mechanism of its action warrants further investigation. This study aims to explore the associations between dietary choline and depression and anxiety in healthy individuals and how these may differ according to genetics, specifically Phosphatidylethanolamine N-Methyltransferase gene involved in endogenous and exogenous choline metabolism. Establishing these associations could reinforce the need for future intervention trials that could in turn establish causality and determine the mechanistic effects of dietary choline and the PEMT gene activity on depression/anxiety

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 50 Years

Healthy volunteers

Yes

Inclusion criteria

* Overall healthy males * pre-menopausal females of 18-50 years of age.

Exclusion criteria

* Individuals with a current clinical diagnosis of anxiety and depression * pregnant or lactating * post-menopausal women * individuals suffering with chronic disease (cardiovascular disease, type-2 diabetes mellitus and cancer) * individuals using choline, lecithin or soy supplements, * obese individuals with a Body Mass Index (BMI) \>30 kg/m2.

Design outcomes

Primary

Measure	Time frame	Description
Depression	1 day observation	Hospital Anxiety and Depression questionnaire score higher than 11
Anxiety	1 day observation	Hospital Anxiety and Depression questionnaire score higher than 11

Secondary

Measure	Time frame	Description
Choline intake	3 day observation	Dietary choline intake
Plasma choline levels	1 measurement	Choline levels in plasma obtained by colorimetry

Countries

United Kingdom

Contacts

Primary ContactLeta Pilic, PhD

leta.pilic@stmarys.ac.uk0208 240 4000

Outcome results